Militia Capital Management LLC Purchases Shares of 23,519 Harrow, Inc. $HROW

Militia Capital Management LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,519 shares of the company’s stock, valued at approximately $829,000.

Other large investors have also recently made changes to their positions in the company. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Harrow during the fourth quarter valued at about $26,000. KBC Group NV acquired a new stake in shares of Harrow in the 1st quarter worth about $31,000. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the 2nd quarter worth about $48,000. SBI Securities Co. Ltd. lifted its position in Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after acquiring an additional 846 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after acquiring an additional 369 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on HROW shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Monday. Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. BTIG Research reiterated a “buy” rating and set a $63.00 price target on shares of Harrow in a report on Tuesday. Cantor Fitzgerald decreased their price target on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, B. Riley Financial reissued a “buy” rating and issued a $65.00 price target (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.43.

Insider Activity at Harrow

In other Harrow news, CFO Andrew R. Boll purchased 3,500 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were acquired at an average cost of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the acquisition, the chief financial officer owned 814,679 shares of the company’s stock, valued at $24,358,902.10. The trade was a 0.43% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adrienne L. Graves acquired 1,000 shares of the business’s stock in a transaction on Monday, May 18th. The stock was acquired at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at approximately $31,070. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 12.80% of the company’s stock.

Harrow Stock Down 2.2%

Harrow stock opened at $41.88 on Friday. Harrow, Inc. has a fifty-two week low of $28.54 and a fifty-two week high of $54.85. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.30 and a current ratio of 2.48. The firm’s 50-day simple moving average is $38.97 and its 200 day simple moving average is $40.87. The stock has a market cap of $1.56 billion, a PE ratio of -102.14 and a beta of 0.26.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. During the same quarter last year, the business posted ($0.38) EPS. Research analysts predict that Harrow, Inc. will post 0.29 EPS for the current fiscal year.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.